Andere talen Argenica Therapeutics Limited

Aandelen

AGN

AU0000150328

Beurs gesloten - Australian S.E. Andere beurzen 07:24:42 18-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
0,58 ^AUD	-1,69%		-8,66%	+13,73%

16/04	ARGENICA THERAPEUTICS LIMITED : Euroz Hartleys herhaalt koopadvies	ZM
28/03	Argenica Therapeutics doneert eerste patiënt in Fase Twee Studie naar Beroerte; Aandelen stijgen met 14%	MT

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Argenica Therapeutics Raises AU$12 Million via Placement	12/04
Argenica Therapeutics Doses First Batch of Patients for Phase Two Stroke Trial	10/04
Argenica Therapeutics Doses First Patient in Phase Two Stroke Trial; Shares Rally 14%	28/03
FDA Grants Argenica Rare Pediatric Disease Designation for Hypoxic Ischaemic Encephalopathy Treatment; Shares Up 16%	25/03
Argenica Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2023	27/02
Argenica Therapeutics Concludes Manufacturing, Release Testing for Stroke Drug; Shares Rise 3%	12/02
Argenica Therapeutics On Track for First Patient Dosing in Phase 2 ARG-007 Trial in Q1 2024	14/12
AusBiotech energised by new Board appointments	11/12
Argenica Therapeutics Appoints Nonexecutive Chair	30/11
Argenica Therapeutics Limited Announces Changes to its Board, Effective 1 December 2023	29/11
Argenica Therapeutics Secures US FDA Orphan Drug Designation for Neurological Medication	15/11
Argenica Therapeutics Secures AU$2 Million R&D Tax Rebate for Fiscal Year 2023	13/11
Argenica Therapeutics Limited Announces the Resignation of Dr. Samantha South as Executive Director Effective 30 November 2023	27-10-23
Argenica Therapeutics' Drug Candidate Reduces Brain Injury in Hypoxic-Ischemic Encephalopathy Preclinical Model	18-10-23
Argenica Therapeutics Secures Ethics Approval for Phase 2 Stroke Trial	12-09-23
Argenica Therapeutics Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-23
Preclinical Data Shows Argenica Therapeutics' ARG-007 Able to Mitigate Neurodegenerative Disorders	02-08-23
Argenica Therapeutics Files Ethics Application for Phase Two Stroke Trial	19-07-23
Argenica Therapeutics Validates Efficacy of Neuroprotective Drug in Preclinical Trial	23-06-23
22,625,752 Ordinary Shares of Argenica Therapeutics Limited are subject to a Lock-Up Agreement Ending on 11-JUN-2023.	11-06-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Argenica Therapeutics Limited

Aandelen

AGN

AU0000150328

Andere talen

Filters